SML1696

HPB

≥98% (HPLC)

• Synonym(s): N-Hydroxy-4-((N-(2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide
• Empirical Formula (Hill Notation): C₁₈H₂₀N₂O₄
• CAS Number: 1800066-24-3
• Molecular Weight: 328.36
• UNSPSC Code: 12352202
• PubChem Substance ID: 329826023

Properties

• assay: ≥98% (HPLC)
• form: powder
• storage condition: protect from light
• color: white to light brown
• solubility: DMSO: 5 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: O=C(N(CCO)CC1=CC=C(C(NO)=O)C=C1)CC2=CC=CC=C2

Description

Biochem/physiol Actions

HPB is a cell-permeable, non-cytotoxic N-hydroxybenzamide derivative that acts as a HDAC6-selective deacetylase inhibitor (IC₅₀ = 31/376/677/842/1133 nM against HDAC6/8/10/1/7, >2 μM against HDAC2/3/4/11/9/5). HPB treatment results in reduced growth, but not viability (up to 64 μM and 72 hrs), of LNCaP prostate cancer cells and non-cancer human foreskin fibroblasts (IC₅₀ = 8 and 16-32 μM, respectively), causing upregulated acetylation levels of alpha-tubulin and peroxiredoxin, but not histones, both in cultures and in mice in vivo. Intraperitoneal injection is efficacious in suppressing the expansion of prostate cancer CWR22 xenograft-derived tumors in mice (by 73% in 4 wks; Five daily 300 mg/kg i.p. dosings a week) without detectable weight loss.

HPB is a cell-permeable, non-cytotoxic N-hydroxybenzamide derivative that acts as a HDAC6-selective deacetylase inhibitor.

Safety Information

• pictograms: GHS07
• signalword: Warning
• hcodes: H319
• pcodes: P305 + P351 + P338
• Hazard Classifications: Eye Irrit. 2
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable